| Soffietti, Riccardo |
| Completed | 2 | 72 | Europe | Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide | International Extranodal Lymphoma Study Group (IELSG) | Primary Central Nervous System Lymphoma | 12/24 | 12/24 | | |
| Recruiting | N/A | 500 | Europe, RoW | Data collection and quality of life questionnaire | Centre Leon Berard | Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation | 06/25 | 06/25 | | |
| Recruiting | N/A | 4975 | Europe, RoW | RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon | European Organisation for Research and Treatment of Cancer - EORTC | All Tumor Types | 03/26 | 03/26 | | |
| Cilloni, Daniela |
| Recruiting | 3 | 172 | Europe | Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD | Gruppo Italiano Malattie EMatologiche dell'Adulto, MYNERVA (MYeloid Neoplasms Research Venture AIRC) programma speciale finanziato dall'AIRC - Associazione Italiana per la, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | Acute Myeloid Leukemia With FLT3/ITD Mutation | 12/22 | 08/25 | | |
| Recruiting | 3 | 414 | Europe | Gemtuzumab Ozogamicin | Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L. | Acute Myeloid Leukemia | 04/25 | 04/27 | | |
| Recruiting | 3 | 274 | Europe | Azacitidine, AZA, Standard Chemotherapy, STD CHT, Allogeneic stem cell transplantation, HSCT | Gruppo Italiano Malattie EMatologiche dell'Adulto, AIFA - Italian Medicines Agency, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | High-risk MDS | 03/24 | 03/24 | | |
| Not yet recruiting | 3 | 339 | Europe, RoW | High intensity therapies, Low intensity therapies | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX | Acute Myeloid Leukemia, Relapse/Recurrence | 01/28 | 01/28 | | |
| Active, not recruiting | 2 | 21 | Europe, US, RoW | GB2064 | Galecto Biotech AB, OPIS s.r.l | Myelofibrosis | 12/23 | 06/26 | | |
| Recruiting | 2 | 32 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA | Chemotherapy, Leukemia, Acute Lymphoblastic | 02/25 | 07/28 | | |
| Active, not recruiting | 2 | 68 | Europe | AG-120 | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes, Acute Myeloid Leukemia | 04/25 | 04/25 | | |
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia |
|
|
| Recruiting | 2 | 118 | Europe, Canada, US, RoW | Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA | Karyopharm Therapeutics Inc | Myelofibrosis, Moderate Thrombocytopenia | 04/26 | 10/28 | | |
| Recruiting | N/A | 343 | Europe, RoW | Questionnaire | Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC | Acute Myeloid Leukemia | 06/21 | 12/22 | | |
NCT03789981: Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia |
|
|
| Active, not recruiting | N/A | 75 | Europe | Immunogenic profile | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Acute Myeloid Leukemia | 12/24 | 12/25 | | |
RUX-MF, NCT06516406: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera |
|
|
| Recruiting | N/A | 1055 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis | 05/32 | 05/32 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 |
|
|
| Recruiting | N/A | 104 | Europe | Venetoclax plus HMA | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 12/22 | 12/23 | | |
| Completed | N/A | 215 | Europe | Luspatercept | Fondazione Italiana Sindromi Mielodisplastiche-ETS, Istituto Clinico Humanitas | Myeloid Dysplasia | 12/22 | 01/23 | | |
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms |
|
|
| Recruiting | N/A | 237 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes | 03/25 | 03/25 | | |
| Not yet recruiting | N/A | 100 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | VEXAS | 02/25 | 06/25 | | |
NCT05553873: Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study. |
|
|
| Recruiting | N/A | 500 | Europe | | University of Milano Bicocca | Myeloproliferative Disease, Inflammatory Markers | 12/26 | 12/26 | | |
| Ferrari, Gaetano De |
| Recruiting | 3 | 80 | Europe | Colchicine, Treatment, Placebo | Niguarda Hospital, European Union, Ministry of Health, Italy, Mario Negri Institute for Pharmacological Research, University of Milano Bicocca | Cardiomyopathies, Myocarditis, Inflammatory Cardiomyopathy, Heart Failure, Ventricular Arrythmia | 05/26 | 05/28 | | |
| Recruiting | 3 | 288 | Europe, US, RoW | Methylprednisolone, saline solution | Niguarda Hospital, Ministry of Health, Italy, Istituto Di Ricerche Farmacologiche Mario Negri, University of Milano Bicocca, Regione Lombardia | Myocarditis Acute | 03/28 | 12/28 | | |
POPSTAR, NCT06294782: PrOsPective Cohort Study for STereotactic Arhythmia Radioablation (STAR) of Refractory Ventricular Tachycardia |
|
|
| Recruiting | N/A | 30 | Europe | STereotactic Arhythmia Radioablation (STAR) | University of Turin, Italy, Azienda Unità Sanitaria Locale Reggio Emilia, IRCCS Sacro Cuore Don Calabria di Negrar, Fondazione IRCCS Policlinico San Matteo di Pavia | Refractory Ventricular Tachycardia | 02/25 | 02/25 | | |
LIVE, NCT04168970: Percutaneous Left Stellate Ganglion Block In Out-of-hospital Cardiac Arrest Due to Refractory VEntricular Arrhythmias ( Study) |
|
|
| Recruiting | N/A | 53 | Europe | PSGB | IRCCS Policlinico S. Matteo, Azienda Regionale Emergenza Urgenza (AREU), University of Pavia | Out-Of-Hospital Cardiac Arrest, Ventricular Fibrillation Sustained | 07/25 | 07/25 | | |
| Recruiting | N/A | 10000 | Europe | | Heart Care Foundation | Heart Failure | 06/26 | 07/26 | | |
| Recruiting | N/A | 100 | Europe | Percutaneous stellate ganglion block (PSGB) | IRCCS Policlinico S. Matteo | Arrhythmic Storm | 12/25 | 12/25 | | |
| Recruiting | N/A | 768 | Europe, RoW | Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site. | Meril Life Sciences Pvt. Ltd. | Aortic Valve Stenosis | 03/24 | 12/33 | | |
NCT04433052: Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD |
|
|
| Recruiting | N/A | 12000 | Europe | personalised prevention program (PPP) | Tampere University | Coronary Heart Disease | 12/26 | 12/26 | | |
| Gianino, Maria Michela |
WORLDCOV, NCT05471635: Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage ( Worldwide Determinants of COVID-19 Vaccination) |
|
|
| Recruiting | N/A | 205 | Europe | COVID-19 Vaccine | Alberto Peano | COVID-19 Vaccines | 07/22 | 07/22 | | |
| Baima, Giacomo |
| Recruiting | N/A | 28 | Europe | Soft tissue augmentation with subepithelial connective tissue graft (SCTG), Soft tissue augmentation with xenogenic volume stable collagen matrix | University of Turin, Italy | Edentulous Alveolar Ridge | 06/23 | 03/24 | | |
NCT05466006: Peri-implant Soft Tissue Volume Changes at Small Buccal Dehiscences |
|
|
| Recruiting | N/A | 28 | Europe | Soft tissue augmentation with subepithelial connective tissue graft (SCTG), Soft tissue augmentation with xenogenic volume stable collagen matrix (VCXM) | University of Turin, Italy | Dental Implants | 12/23 | 06/24 | | |
| Grottoli, Silvia |
| Recruiting | N/A | 30 | Europe | SGLT2 inhibitor, Dapagliflozin, Empagliflozin, Canagliflozin | University of Turin, Italy | Diabetes Mellitus, Type 2, Arterial Hypertension, Body Weight Changes | 07/20 | 10/20 | | |
| DiStefano, Marco |
| Completed | N/A | 515 | Europe | | University of Turin, Italy, Gilead Sciences | Chronic Hepatitis D | 06/24 | 12/24 | | |
| Enrolling by invitation | N/A | 287 | Europe, RoW | | University of Edinburgh, European Research Council | Paget Disease | 12/24 | 12/24 | | |
| Dr, Riccardo Soffietti |
| Active, not recruiting | 2/3 | 140 | Europe, RoW | LAM561, TMZ, RT | Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS | Primary Glioblastoma, Glioblastoma Multiforme | 10/24 | 05/25 | | |
| Pia, Lorenzo |
| Recruiting | 1 | 45 | Europe | VR_Training_1PP, VR_Training_3PP | University of Turin, Italy, HastaFisio - Fisioterapia e Medicina dello Sport | Knee Injuries | 04/25 | 12/25 | | |
| Pyasik, Maria |
| Recruiting | 1 | 45 | Europe | VR_Training_1PP, VR_Training_3PP | University of Turin, Italy, HastaFisio - Fisioterapia e Medicina dello Sport | Knee Injuries | 04/25 | 12/25 | | |
| Boccia, Gennaro |
| Recruiting | 1 | 45 | Europe | VR_Training_1PP, VR_Training_3PP | University of Turin, Italy, HastaFisio - Fisioterapia e Medicina dello Sport | Knee Injuries | 04/25 | 12/25 | | |
| Peano, Alberto |
WORLDCOV, NCT05471635: Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage ( Worldwide Determinants of COVID-19 Vaccination) |
|
|
| Recruiting | N/A | 205 | Europe | COVID-19 Vaccine | Alberto Peano | COVID-19 Vaccines | 07/22 | 07/22 | | |
| Politano, Gianfranco |
WORLDCOV, NCT05471635: Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage ( Worldwide Determinants of COVID-19 Vaccination) |
|
|
| Recruiting | N/A | 205 | Europe | COVID-19 Vaccine | Alberto Peano | COVID-19 Vaccines | 07/22 | 07/22 | | |
| Alonso, Miriam |
| Active, not recruiting | 2/3 | 140 | Europe, RoW | LAM561, TMZ, RT | Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS | Primary Glioblastoma, Glioblastoma Multiforme | 10/24 | 05/25 | | |
| Recruiting | 2 | 40 | Europe | Carboplatin, Paraplatin, Paclitaxel, Taxol, Nivolumab, Opdivo | Fundación GECP, Bristol-Myers Squibb Pharma | NSCLC, Pancoast Tumor | 03/28 | 06/28 | | |
| Mandrile, Giorgia |
| Recruiting | N/A | 30000 | Europe, US, RoW | GWAS | Cyprus Institute of Neurology and Genetics | Sickle Cell Disease, Thalassemia, Beta, Thalassemia Alpha, Hemoglobinopathies | 09/27 | 09/27 | | |
| Col, Matteo Da |
| Recruiting | 1 | 45 | Europe | VR_Training_1PP, VR_Training_3PP | University of Turin, Italy, HastaFisio - Fisioterapia e Medicina dello Sport | Knee Injuries | 04/25 | 12/25 | | |
